Double Bond Pharamceutical AB acquires Temodex, a locally acting brain tumor therapy based on temozolomide
· DBP will expand and diversify the company’s portfolio by acquiring Temodex indicated for the treatment of glioblastoma from RI PCP in Belarus · This transaction underscores DBP’s commitment to become a leading supplier of first-in-class drug delivery platforms, offering patients a wide range of treatments for oncology diseases while simultaneously delivering value to shareholders · DBP will acquire the global rights to Temodex, excluding the Eurasian Economic Union and Ukraine Double Bond Pharmaceutical AB announced today that it has entered into an agreement for the acquisition